Walter Goljan, MD
Internal Medicine · Worcester, MANPI 1619942679
Payments from drug & device makers
Across 194 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$919
- AstraZeneca$633
- Boehringer Ingelheim$452
- Novo Nordisk$372
- Johnson & Johnson$171
- Merck$157
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,873100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 43 | $919 |
| AstraZeneca | 34 | $633 |
| Boehringer Ingelheim | 24 | $452 |
| Novo Nordisk | 17 | $372 |
| Johnson & Johnson | 9 | $171 |
| Merck | 9 | $157 |
| Inspire Medical Systems, Inc. | 7 | $153 |
| E.r. Squibb & Sons, L.L.C. | 6 | $143 |
| Pfizer | 6 | $112 |
| Amarin Pharma, Inc. | 5 | $91 |
| Daiichi Sankyo Inc. | 5 | $85 |
| Abbott | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| Exact Sciences | 3 | $66 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| GSK | 2 | $42 |
| Sanofi Pasteur Inc. | 3 | $40 |
| Agios Pharmaceuticals, Inc. | 1 | $38 |
| Novartis | 2 | $31 |
| Ardelyx, Inc. | 1 | $25 |
| AbbVie | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Bayer | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Mylan Specialty L.p. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$3,873 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 87 | $80,306 |
| OzempicSemaglutide | 46 | $51,969 |
| EliquisApixaban | 32 | $36,617 |
| JanuviaSitagliptin Phosphate | 25 | $25,451 |
| TradjentaLinagliptin | 25 | $23,380 |
| FarxigaDapagliflozin Propanediol | 12 | $13,373 |
| LinzessLinaclotide | 15 | $12,467 |
| TrulicityDulaglutide | 11 | $12,437 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $10,509 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,995 |
| Atorvastatin Calcium | 387 | $4,818 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,710 |
| Metoprolol Succinate | 189 | $3,630 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,660 |
| Simvastatin | 252 | $2,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $452 | $109,681124 claims |
| Novo NordiskOzempic | $372 | $51,96946 claims |
| PfizerEliquis | $112 | $36,61732 claims |
| MerckJanuvia | $157 | $25,45125 claims |
| AbbVieLinzess, Synthroid | $25 | $14,30743 claims |
| GSKBreo Ellipta, Incruse Ellipta | $42 | $14,21923 claims |
| AstraZenecaFarxiga | $633 | $13,37312 claims |
| Lilly USA, LLCTrulicity | $919 | $12,43711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Worcester
- Deepa JagadeeshWorcester$5.6M
- Jee BangWorcester$2.8M
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.